Creighton Medical Laboratories First to Offer New Cancer Test
The method, called SNP array karyotyping, has been successfully used in
research laboratories to study cancer for several years. However, Creighton Medical Laboratories, using AffymetrixTM SNP arrays, is the first laboratory to validate the test in a clinical setting and make it available for routine clinical use.
The method can help doctors make more accurate cancer diagnoses and tailor patient management based on the DNA profiles of each person’s cancer.
Array-based karyotyping is a 21st century spin on older genetic testing methods that have helped guide patient care for decades. DNA is bundled inside cells as chromosomes; a karyotype is a representation of all of the chromosomes in a cell. Normal human cells have two copies of each
chromosome. Cancer cells will often duplicate or lose pieces of chromosomes, and these chromosomal changes can help physicians categorize a tumor, determine its aggressiveness, and/or determine which tumors will respond to specific drugs.
With the new method being used at Creighton Medical Laboratories, DNA from
tumor cells is applied to the arrays and scanned into a computer. The chromosomes are reconstructed by the computer to provide a genome-wide view of the cancer cells at unprecedented resolution; physicians then ‘surf’ the cancer genome using web-based genome browsers.
“SNP array karyotyping is a powerful new tool in our molecular tool box,” said
The SNP (single nucleotide polymorphism) array used by
“As an example, with SNP-array virtual karyotypes, we have detected copy neutral LOH at important regions of the cancer genome, like the p53 gene in chronic lymphocytic leukemia. If the tumor has no functional copies of this important gene, it tends to behave aggressively, and the treating physician may want to treat it more aggressively,” Hagenkord said. “This genetic lesion would not have been detectable with the current testing methods, which really underscores the importance of having this new testing method available clinically.”
“We are very fortunate to have Dr. Hagenkord at the helm in clinical genomics, since she is currently the only pathologist worldwide with fellowship training in both molecular genetic pathology and pathology/oncology informatics. She has been performing SNP array karyotyping of tumors since the technology emerged and she is truly an expert in the field.”
For more information about the clinic, Hagenkord and SNP array karyotyping, visit http://cml.md.
About Creighton Medical Laboratories: (CML) is a leading provider of diagnostic medical testing and consultative services. Through its affiliation with
This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.